- Home
- AZTA vs WVE Comparison
AZTA vs WVE Comparison
Compare AZTA & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTA
- WVE
- Stock Information
- Founded
- AZTA 1978
- WVE 2012
- Country
- AZTA United States
- WVE Singapore
- Employees
- AZTA N/A
- WVE N/A
- Industry
- AZTA Industrial Machinery/Components
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- AZTA Technology
- WVE Health Care
- Exchange
- AZTA Nasdaq
- WVE Nasdaq
- Market Cap
- AZTA 1.8B
- WVE 1.7B
- IPO Year
- AZTA 1995
- WVE 2015
- Fundamental
- Price
- AZTA $34.29
- WVE $8.62
- Analyst Decision
- AZTA Buy
- WVE Strong Buy
- Analyst Count
- AZTA 4
- WVE 11
- Target Price
- AZTA $58.75
- WVE $22.00
- AVG Volume (30 Days)
- AZTA 737.8K
- WVE 1.3M
- Earning Date
- AZTA 05-07-2025
- WVE 03-04-2025
- Dividend Yield
- AZTA N/A
- WVE N/A
- EPS Growth
- AZTA N/A
- WVE N/A
- EPS
- AZTA N/A
- WVE N/A
- Revenue
- AZTA $662,108,000.00
- WVE $108,302,000.00
- Revenue This Year
- AZTA N/A
- WVE N/A
- Revenue Next Year
- AZTA $5.58
- WVE $33.28
- P/E Ratio
- AZTA N/A
- WVE N/A
- Revenue Growth
- AZTA 5.36
- WVE N/A
- 52 Week Low
- AZTA $33.37
- WVE $4.25
- 52 Week High
- AZTA $63.58
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- AZTA 30.18
- WVE 36.64
- Support Level
- AZTA $35.06
- WVE $9.43
- Resistance Level
- AZTA $38.57
- WVE $10.91
- Average True Range (ATR)
- AZTA 1.73
- WVE 0.70
- MACD
- AZTA 0.06
- WVE -0.07
- Stochastic Oscillator
- AZTA 4.11
- WVE 5.45
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.